Comprehensive therapy

Comprehensive therapy has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Oct 11, 2026: “DYNAMICS OF MYOKINE STATUS AND METABOLIC PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND SARCOPENIA RECEIVING COMPREHENSIVE THERAPY”.

Intervention

1 paper studies it5 findingsUpdated

See all 1 papers on comprehensive therapy

At a glance

The findings reach people, from one lab or study. 1 lab.

“the reduction in insulin resistance was more pronounced in Group 1 (HOMA-IR decreased 1.74-fold versus 1.41-fold in Group 2)”
DYNAMICS OF MYOKINE STATUS AND METABOLIC PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND SARCOPENIA RECEIVING COMPREHENSIVE THERAPYSOUTH ARAL SEA MEDICAL JOURNAL2026doi:10.5281/zenodo.23303534

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab
  • Human trial1

Studies in people

1 study gave comprehensive therapy to people and measured what changed.

What changedDesignPeopleSource

down: Decreases HOMA-IR1.74-fold versus 1.41-fold

down: Decreases myostatindecreased by 33.6%

up: Increases irisin1.67-fold

Trialsix months35 people55 to 65 yearsMidlife adults; sarcopenia group (Group 1) compared with T2DM without sarcopeniaSOUTH ARAL SEA MEDICAL JOURNAL, Oct 11, 2026

What did studies of comprehensive therapy find?

5

Studies of comprehensive therapy measured 5 outcomes, among them vitamin D, handgrip strength and irisin.

Vitamin D

upin humans1

1 study
  1. Comprehensive therapy increases vitamin D in humans (patients with sarcopenia).

    “vitamin D reached optimal values”

    Human trialpatients with sarcopeniasix monthsn = 35

    DYNAMICS OF MYOKINE STATUS AND METABOLIC PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND SARCOPENIA RECEIVING COMPREHENSIVE THERAPY

    SOUTH ARAL SEA MEDICAL JOURNAL

More on Vitamin D

Handgrip strength

upin humans1

1 study
  1. Comprehensive therapy increases handgrip strength in humans (patients with sarcopenia).

    “These changes were accompanied by significant gains in handgrip strength”

    Human trialpatients with sarcopeniasix monthsn = 35

    DYNAMICS OF MYOKINE STATUS AND METABOLIC PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND SARCOPENIA RECEIVING COMPREHENSIVE THERAPY

    SOUTH ARAL SEA MEDICAL JOURNAL

Irisin

upin humans1

1 study
  1. Comprehensive therapy increases irisin in humans (patients with sarcopenia) (1.67-fold).

    “irisin increased 1.67-fold”

    Human trialpatients with sarcopeniasix monthsn = 35

    DYNAMICS OF MYOKINE STATUS AND METABOLIC PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND SARCOPENIA RECEIVING COMPREHENSIVE THERAPY

    SOUTH ARAL SEA MEDICAL JOURNAL

More on Irisin

Myostatin

downin humans1

1 study
  1. Comprehensive therapy decreases myostatin in humans (patients with sarcopenia) (decreased by 33.6%).

    “In patients with sarcopenia, serum myostatin decreased by 33.6%”

    Human trialpatients with sarcopeniasix monthsn = 35

    DYNAMICS OF MYOKINE STATUS AND METABOLIC PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND SARCOPENIA RECEIVING COMPREHENSIVE THERAPY

    SOUTH ARAL SEA MEDICAL JOURNAL

More on Myostatin

HOMA-IR

downin humans1

1 study
  1. Comprehensive therapy decreases HOMA-IR in humans (sarcopenia group (Group 1) compared with T2DM without sarcopenia) (1.74-fold versus 1.41-fold).

    “the reduction in insulin resistance was more pronounced in Group 1 (HOMA-IR decreased 1.74-fold versus 1.41-fold in Group 2)”

    Human trialsarcopenia group (Group 1) compared with T2DM without sarcopeniasix monthsn = 35

    DYNAMICS OF MYOKINE STATUS AND METABOLIC PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND SARCOPENIA RECEIVING COMPREHENSIVE THERAPY

    SOUTH ARAL SEA MEDICAL JOURNAL

More on HOMA-IR

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 01 paper in 12 months